Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: Examples of the present disclosure describe systems and methods for visit detection. More particularly, the described systems and methods relate to improving venue coverage distribution as applied to visit detection models. In aspects, the visit detection system/model of a mobile device may predict that a user is visiting a supervenue based on a set of venue visit probabilities. The visit probability for the supervenue may be redistributed among the subvenues of the supervenue to create a subvenue visit probability distribution. Based on the probability redistribution, the visit detection system/model may predict speculatively that the user is visiting (or has checked into) a particular subvenue. Examples of the present disclosure further described an importance reweighting process may be used to correct the bias in data sets used to train/configure the visit detection system/model.

Abstract: Examples of the present disclosure describe systems and methods for venue detection. In aspects, a mobile device comprising a set of sensors may collect and store sensor data from in response to a detected movement event or user interaction data. The sensor data may be used to generate a set of candidate venues corresponding to the location of the mobile device. The candidate venues may be provided to a venue detection system. The venue detection system may process the candidate venues to generate a set of features. The set of features may be applied to, and/or used to generate, one or more probabilistic models. The probabilistic models may generate confidence metrics for each of the candidate venues. In some aspects, the top ‘N’ venues may be selected from the set. The top ‘N’ venues may then be presented to the user and/or used to effect one or more actions.

Abstract: An animal protective garment includes a body, legs and integral boots. The legs may include openings covered by flaps. The openings provide access to the interior of the garment so that a person may properly position an animal's foot or paw within integral boots. The garment may include a lining for comfort and patches of durable material. The integral boots may also include durable soles.

Abstract: A method and a system for analyzing turbomachinery are provided. In one embodiment, a system for analyzing turbomachinery is provided. The system includes an intelligent turbomachinery filter (ITF) system configured to analyze a historical sensor data for one or more components of a turbomachine to produce a filtered trend. The system further includes a detection and diagnostic system configured to determine a root cause of a turbomachine performance based on the filtered trend.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and, a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.

Abstract: A method of solubilizing an analog active agent of the prostaglandin F2?, such as latanoprost, is described and a method of preparing an ophthalmic solution of the solubilized latanoprost for the treatment of distinct ocular ailments. This invention also refers to an ophthalmic aqueous solution resulting from the aforementioned method, which is characterized by its chemical stability at room temperature, its safety, and innocuousness and efficiency in the treatment of the patient. The new ophthalmic aqueous solution is distinguished because its pharmaceutical value is found in the handling of a vehicle of easy access that not only permits the solubility of latanoprost, but also promotes its chemical stability and a greater tolerance of the patient with its ophthalmic application for the treatment of the patient's ailment.